Multicenter prospective study for clinical and endoscopic efficacies of leukocytapheresis therapy in patients with ulcerative colitis

References

• Targan SR, Karp LC. Defects in mucosal immunity leading to ulcerative colitis. Immunol Rev 2005;206:296–305.
   PubMed Web of Science ®Google Scholar
• Grimm MC, Pullman WE, Bennett GM, Sullivan PJ, Pavli P, Doe WF. Direct evidence of monocyte recruitment to inflammatory bowel disease mucosa. J Gastroenterol Hepatol 1995;10:387–95.
   PubMed Web of Science ®Google Scholar
• Moertel CG, Bargen JA. A critical analysis of the use of salicylazosulfapyridine in chronic ulcerative colitis. Ann Intern Med 1959;51:879–89.
   PubMed Web of Science ®Google Scholar
• Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625–9.
   PubMed Web of Science ®Google Scholar
• Truelove SC, Witts LJ. Cortisone and corticotrophin in ulcerative colitis. Br Med J 1959;34:387–94.
   Google Scholar
• Meyers S, Sachar DB, Goldberg JD, Janowitz HD. Corticotropin versus hydrocortisone in the intravenous treatment of ulcerative colitis: a prospective, randomized, double blind clinical trial. Gastroenterology 1983;85:351–7.
   PubMed Web of Science ®Google Scholar
• Mackay IR, Wall AJ, Goldstein G. Response to azathioprine in ulcerative colitis. Report of 7 cases. Am J Dig Dis 1966;11:536–45.
   Google Scholar
• Hibi T, Sakuraba A. Is there a role for apheresis in gastrointestinal disorders? Nat Clin Pract Gastroenterol Hepatol 2005;2:200–1.
   PubMedGoogle Scholar
• Sawada K, Ohnishi K, Fukui S, Yamada K, Yamamura M, Amano K, Leukocytapheresis therapy, performed with leukocyte removal filter, for inflammatory bowel disease. J Gastroenterol 1995;30:322–9.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ. Preliminary data on the use of apheresis in inflammatory bowel disease. Inflamm Bowel Dis 2006;12:S15–21.
   PubMed Web of Science ®Google Scholar
• Emmrich J, Petermann S, Nowak D, Beutner I, Brock P, Klingel R, Leukocytapheresis (LCAP) in the management of chronic active ulcerative colitis-results of a randomized pilot trial. Dig Dis Sci 2007;52:2044–53.
   PubMedGoogle Scholar
• Sawada K, Muto T, Shimoyama T, Satomi M, Sawada T, Nagawa H, Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column. Curr Pharm Des 2003;9:307–21.
   PubMed Web of Science ®Google Scholar
• Nishioka C, Aoyama N, Maekawa S, Shirasaka D, Nakahara T, Tamura T, Leukocytapheresis therapy for steroid-naïve patients with active ulcerative colitis: its clinical efficacy and adverse effects compared with those of conventional steroid therapy. J Gastroenterol Hepatol 2005;20:1567–71.
   PubMedGoogle Scholar
• Sawada K, Kusugami K, Suzuki Y, Bamba T, Munakata A, Hibi T, Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment. Am J Gastroenterol 2005;100:1362–9.
   PubMed Web of Science ®Google Scholar
• Matsumoto T, Andoh A, Okawa K, Ito H, Torii A, Yoshikawa S, Multivariate analysis for factors predicting rapid response of leukocytapheresis in patients with steroid-resistant ulcerative colitis: a multicenter prospective open-label study. Ther Apher Dial 2008;12:484–90.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462–76.
   PubMed Web of Science ®Google Scholar
• Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989;14:82–6.
   Google Scholar
• Froslie KF, Jahnsen J, Moum BA, Vatn MH; IBSEN Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007;133:412–42.
   PubMed Web of Science ®Google Scholar
• Pineton de Chambrun G, Peyrin-Biroulet L, Lemann M, Colombel JF. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 2010;7:15–29.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y, Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011;141:1194–201.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Umegae S, Matsumoto K. Mucosal healing in patients with ulcerative colitis during a course of selective leukocytapheresis therapy: a prospective cohort study. Inflamm Bowel Dis 2010;16:1905–11.
   PubMed Web of Science ®Google Scholar
• Talstad I, Rootwelt K, Gjone E. Thrombocytosis in ulcerative colitis and Crohn's disease. Scand J Gastroenterol 1973;8:135–8.
   PubMed Web of Science ®Google Scholar
• Van Wersch JW, Houben P, Rijken J. Platelet count, platelet function, coagulation activity and fibrinolysis in the acute phase of inflammatory bowel disease. J Clin Chem Clin Biochem 1990;28:513–17.
   PubMedGoogle Scholar
• Kapsoritakis AN, Koukourakis MI, Sfiridaki A, Potamianos SP, Kosmadaki MG, Koutroubakis IE, Mean platelet volume; a useful marker of inflammatory bowel disease activity. Am J Gastroenterol 2001;96:776–81.
   PubMed Web of Science ®Google Scholar
• Harries AD, Fitzsimons E, Fifield R, Dew MJ, Rhoades J. Platelet count: a simple measure of activity in Crohn's disease. Am J Gastroenterol 2004;99:938–45.
   Google Scholar
• Danese S, Scaldaferri F, Papa A, Pola R, Sans M, Gasbarrini G, Platelets: new players in the mucosal scenario of inflammatory bowel disease. Riv Eur Sci Med Farmacol 2004;8:193–8.
   Google Scholar
• Yagi Y, Andoh A, Inatomi O, Bamba S, Tsujikawa T, Fujiyama Y, Modulation of platelet aggregation responses by leukocytapheresis therapy in patients with active ulcerative colitis. J Gastroenterol 2006;41:540–6.
   PubMedGoogle Scholar
• Fukunaga K, Fukuda Y, Yokoyama Y, Ohnishi K, Kusaka T, Kosaka T, Activated platelets as a possible early marker to predict clinical efficacy of leukocytapheresis in severe ulcerative colitis patients. J Gastroenterol 2006;41:524–32.
   PubMedGoogle Scholar
• Takemoto K, Kuriyama K, Kato J, Suzuki H, Ishikawa S, Hiraoka S, Ratio of platelet reduction is an early predictive factor for the effectiveness of leukocytapheresis for ulcerative colitis patients. Ther Apher Dial 2009;13:6–13.
   Google Scholar